139
Views
17
CrossRef citations to date
0
Altmetric
Articles

WHICH ONE IS A RISK FACTOR FOR CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN CHILDHOOD SOLID TUMORS: Early Lymphopenia or Monocytopenia?

, MD, , MD, , MD & , MD
Pages 143-151 | Received 18 May 2005, Accepted 01 Nov 2005, Published online: 09 Jul 2009
 

Abstract

Neutropenia is one of the undesirable effects of cancer chemotherapy, sometimes causing life-threatening events. The present study was conducted to identify the risk factors of neutropenia caused by chemotherapy. Between January 2001 and March 2004, a total of 77 children with 165 neutropenic attacks were enrolled in this study. Complete blood count was performed before chemotherapy and on days 1, 3, 5, 7, and 9 consecutively. The complete blood count results of the febrile neutropenia (FN) group were compared to those of the non-FN group. The incidence of FN was significantly higher in patients with ANC counts ≤0.5 × 109/L on days 3, 5, and 7, lymphocyte counts ≤0.5 × 109/L on days 7 and 9, ≤0.7 × 109/L on days 5, 7, and 9, and with monocyte counts ≤0.15 × 109/L on days 7 and 9, respectively. Further statistical analysis showed that lymphocyte count ≤0.7 × 109/L on day 5, and monocyte count ≤0.15 × 109/L on day 7 were independent risk factors for FN. The authors conclude that lymphocyte counts on the 5th day can be more a predictive factor than monocyte count.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.